CLINICAL_TRIALS
trial_result
· 2024-03-05
Clinical Trial Update: BMS-986012 in Relapsed/Refractory SCLC [Phase 1, Phase 2]
Summary
Phase 1/2 trial updates for BMS-986012 in relapsed/refractory small cell lung cancer are completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-05